SRR612311
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.527
- INTERFERON_ALPHA_RESPONSE+0.517
- ALLOGRAFT_REJECTION+0.510
- IL6_JAK_STAT3_SIGNALING+0.471
- INFLAMMATORY_RESPONSE+0.468
- TNFA_SIGNALING_VIA_NFKB+0.466
- ANGIOGENESIS+0.419
- IL2_STAT5_SIGNALING+0.394
- CHOLESTEROL_HOMEOSTASIS+0.361
- COMPLEMENT+0.357
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.480
- OXIDATIVE_PHOSPHORYLATION-0.450
- PANCREAS_BETA_CELLS-0.359
- UV_RESPONSE_DN-0.242
- MYC_TARGETS_V2-0.229
- DNA_REPAIR-0.176
- ADIPOGENESIS-0.162
- KRAS_SIGNALING_DN-0.161
- MYC_TARGETS_V1-0.155
- UNFOLDED_PROTEIN_RESPONSE-0.112
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1073755 | GTEX | — | 0.974 |
| 2 | SRR1468403 | GTEX | — | 0.940 |
| 3 | SRR1402840 | GTEX | — | 0.911 |
| 4 | SRR1350525 | GTEX | — | 0.910 |
| 5 | SRR1368856 | GTEX | — | 0.907 |
| 6 | SRR1387989 | GTEX | — | 0.903 |
| 7 | SRR615731 | GTEX | — | 0.886 |
| 8 | SRR1441701 | GTEX | — | 0.886 |
| 9 | SRR1079168 | GTEX | — | 0.885 |
| 10 | SRR602871 | GTEX | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.527 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.517 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.471 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.468 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.466 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.419 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.394 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.361 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.357 | Inavolisib | — uncovered |
| APOPTOSIS | 0.342 | Idelalisib | — uncovered |
| COAGULATION | 0.336 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.218 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.211 | Inavolisib | — uncovered |
| HYPOXIA | 0.191 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.178 | Idelalisib | — uncovered |
| MYOGENESIS | 0.155 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.145 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.144 | Inavolisib | — uncovered |